Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient

O. Olisova, E. Anpilogova, D. Svistunova,

2021

https://doi.org/10.1111/dth.13668

Цитирование

Об авторах

O. Olisova
Dermatology Department, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
E. Anpilogova
D. Svistunova

Название журнала

Том

Выпуск

Страницы

Ключевые слова

apremilast; methotrexate; apremilast; thalidomide; adult; case report; clinical article; coronavirus disease 2019; human; Letter; male; middle aged; nose smear; psoriasis; PUVA; quarantine; recommended drug dose; remission; systemic therapy; throat culture; treatment duration; Betacoronavirus; Coronavirus infection; intensive care; oligodendroglioma; pandemic; psoriatic arthritis; virus pneumonia; Arthritis, Psoriatic; Betacoronavirus; Coronavirus Infections; Critical Care; Humans; Infections; Oligodendroglioma; Pandemics; Pneumonia, Viral; Thalidomide

Издатель

Тип документа

Источник